Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Phase 3positiveZasocitinibDeucravacitinibPositive

AI Analysis

Summary

Zasocitinib demonstrated superior efficacy compared to deucravacitinib in a Phase 3 head-to-head trial, showing rapid and durable skin clearance in a once-daily oral formulation.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Zasocitinib delivered superior efficacy versus deucravacitinib in head-to-head Phase 3 results with rapid and durable skin clearance in once-daily pill formulation

Importance:7/10

Sentiment:

0.80

Phase 3 datahead-to-head trialdermatologycompetitive advantage

Related Companies

$TKPHF

Read the original article

Published by yahoo_finance on September 30, 2026 5:00 AM

Read Original